[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367317-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367317-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-value-of-circulating-hpv-cell-free-dna-in-cervical-cancer-using-liquid-biopsy","Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy","","Liquid biopsies enabling blood-based analysis of circulating tumor cells and circulating cell-free DNA (ctDNA) are increasingly used for cancer detection and monitoring. This study evaluates droplet digital PCR (ddPCR) for detecting and quantifying circulating human papillomavirus (HPV) cell-free DNA in cervical cancer patients at baseline and during follow-up as a prognostic marker. Plasma from 60 patients and 10 healthy controls was analyzed for high-risk HPV16 and HPV18, with ddPCR showing differential detection rates and associations between HPV16 levels and tumor size.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-circulating-hpv-cell-free-dna-in-cervical-cancer-using-liquid-biopsy/367317/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-circulating-hpv-cell-free-dna-in-cervical-cancer-using-liquid-biopsy/367317.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of using ddPCR in this study?","Question",{"text":63,"@type":64},"To detect and quantify circulating HPV cell-free DNA in cervical cancer patients at baseline and during follow-up, and evaluate its utility as a prognostic marker.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were samples collected and processed?",{"text":68,"@type":64},"Blood samples were collected from 60 cervical cancer patients at baseline and three months post-treatment, and from 10 healthy controls. Plasma was separated, stored at −80 °C, and cfDNA was extracted from plasma.",{"name":70,"@type":61,"acceptedAnswer":71},"Which high-risk HPV types were assessed, and what detection rates were reported?",{"text":72,"@type":64},"HPV16 and HPV18 were assessed in cfDNA using ddPCR, with detection rates of 82.86% for HPV16 and 45.71% for HPV18.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367317,1790939402,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPrognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy  \nAshna Gupta1, Gunjan Dagar1, Sumit Kr. Das2, Ravi Chauhan1, Abhishek Shankar3, Daya Nand Sharma3, Vaishali Suri4, Maroof Ahmad Khan2, Muzafar A. Macha5, Ikhlak Ahmed6, Ammira S. Al-ShabeebAkil6, AjazA. Bhat6􀀍 & Mayank Singh1􀀍  \nLiquid biopsies, which analyze circulating tumor cells or cell-free circulating tumor DNA (ctDNA) from blood, have emerged as promising cancer detection and monitoring tools. Specifically, human papillomavirus (HPV) cell-free (cf) DNA is gaining recognition as a prognostic marker in high-risk HPV-related cancers. However, detecting circulating markers for cervical cancer (CC) requires highly sensitive techniques to quantify circulating HPV DNA. This study aimed to evaluate the use of droplet digital PCR (ddPCR), a highly sensitive technique, for detecting and quantifying circulating HPV DNA in cervical cancer patients, both at baseline (before chemo-or radiotherapy) and during follow-up, to assess its utility as a prognostic marker. Blood samples were collected from 60 cervical cancer patients (Stages I–IV) atAIIMS, New Delhi, at baseline and three months post-treatment. Samples from 10 healthy controls were also included. Plasma was separated and stored at − 80 °C, and cfDNA was extracted from 1 ml of plasma. The presence of high-risk HPV types, HPV16 and HPV18, in cfDNA from 35 patients was assessed using ddPCR. The median concentration of cfDNA in cervical cancer patients was 9.35 ng/µL at baseline, which decreased to 7 ng/µL after three months of treatment. In healthy controls, the median cfDNA concentration was 6.95 ng/µL. ddPCR screening showed that detection rates for HPV18 and HPV16 detection were 45.71% and 82.86%, respectively. A significant correlation was observed between cf HPV16 DNA levels and tumor size, suggesting its potential as biomarker for disease burden.  \nKeywords Cervical cancer, Digital droplet PCR, Human papillomavirus, Circulating tumor DNA, Circulating cell-free DNA  \nAbbreviations  \ncfDNA  \nccfDNA  \nctDNA ddPCR HPV ccfHPV DNA rHPVs HPV18  \nHPV16 SCCNKSCCCAAAUC  \nCell-free DNA Circulating cell-free DNA Circulating tumor DNA  \nDigital droplet polymerase chain reaction  \nHuman papillomavirus Circulating cell-free HPV DNA High-risk human papillomaviruses Human papillomavirus 18  \nHuman papillomavirus 16  \nSquamous cell carcinoma Non-squamous cell carcinoma Clear cell adenocarcinomas Area under the curve  \n1Department of Medical Oncology (Lab), Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. 2Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India. 3Radiation Oncology Unit, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. 4Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.  \n5Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Jammu and Kashmir, India. 6Department of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar. 􀀍 email: [abhat@sidra.org](abhat@sidra.org); [mayank.osu@gmail.com](mayank.osu@gmail.com); [mayank.singh@aiims.edu](mayank.singh@aiims.edu)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nCervical cancer (CC) is the fourth most common malignancy among women worldwide, posing a significant threat to women’s health. Despite widespread Pap smear screening programs, cervical cancer remains a major concern, with an estimated 662,301 cases and 348,874 deaths reported globally in 2022 (IARC, 2022) . In India, there were 127,526 cases and 79,906 related deaths, underscoring the need for more effective diagnostic and monitoring strategies (WCRF, 2022) . Common symptoms of cervical cancer inc","cbCaijrH2TOgcKXO","https://ap.wps.com/l/cbCaijrH2TOgcKXO","pdf",2270223,"English","# Introduction\n## Liquid biopsy and ctDNA/ccfDNA rationale\n## HPV DNA as a prognostic biomarker\n## Challenges with current detection methods\n# Methods\n## Study design and sample collection\n## ddPCR detection of HPV16/HPV18\n# Results\n## cfDNA concentration changes after treatment\n## ddPCR detection rates and correlations","[{\"question\":\"What was the purpose of using ddPCR in this study?\",\"answer\":\"To detect and quantify circulating HPV cell-free DNA in cervical cancer patients at baseline and during follow-up, and evaluate its utility as a prognostic marker.\"},{\"question\":\"How were samples collected and processed?\",\"answer\":\"Blood samples were collected from 60 cervical cancer patients at baseline and three months post-treatment, and from 10 healthy controls. Plasma was separated, stored at −80 °C, and cfDNA was extracted from plasma.\"},{\"question\":\"Which high-risk HPV types were assessed, and what detection rates were reported?\",\"answer\":\"HPV16 and HPV18 were assessed in cfDNA using ddPCR, with detection rates of 82.86% for HPV16 and 45.71% for HPV18.\"}]","Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy | PDF",1790170226,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b8933c752b56a0de614335cb553be14.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1bd45c22017e69cd1fb9af7249939d6.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60f05dc6e579d5407fa7da71cbbbd722.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/874fd9aa47a5b78456be31e3ff1a9ae2.webp",980,1287]